Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
MELA's Cash to Debt is ranked higher than
95% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.33 vs. MELA: No Debt )
MELA' s 10-Year Cash to Debt Range
Min: 2.83   Max: No Debt
Current: No Debt

Equity to Asset 0.57
MELA's Equity to Asset is ranked higher than
69% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. MELA: 0.57 )
MELA' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.94
Current: 0.57

0.37
0.94
F-Score: 3
Z-Score: -23.34
M-Score: 0.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -3433.63
MELA's Operating margin (%) is ranked lower than
54% of the 306 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.78 vs. MELA: -3433.63 )
MELA' s 10-Year Operating margin (%) Range
Min: -8174.46   Max: -869.05
Current: -3433.63

-8174.46
-869.05
Net-margin (%) -3391.94
MELA's Net-margin (%) is ranked lower than
54% of the 306 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.09 vs. MELA: -3391.94 )
MELA' s 10-Year Net-margin (%) Range
Min: -8155.76   Max: -1085.71
Current: -3391.94

-8155.76
-1085.71
ROE (%) -195.18
MELA's ROE (%) is ranked lower than
52% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.62 vs. MELA: -195.18 )
MELA' s 10-Year ROE (%) Range
Min: -233.02   Max: -53.54
Current: -195.18

-233.02
-53.54
ROA (%) -115.66
MELA's ROA (%) is ranked lower than
53% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.65 vs. MELA: -115.66 )
MELA' s 10-Year ROA (%) Range
Min: -502.58   Max: -50.87
Current: -115.66

-502.58
-50.87
ROC (Joel Greenblatt) (%) -317.20
MELA's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.33 vs. MELA: -317.20 )
MELA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4892.42   Max: -403.68
Current: -317.2

-4892.42
-403.68
EBITDA Growth (%) -13.20
MELA's EBITDA Growth (%) is ranked higher than
58% of the 234 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. MELA: -13.20 )
MELA' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -1
Current: -13.2

EPS Growth (%) -10.00
MELA's EPS Growth (%) is ranked higher than
61% of the 241 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.40 vs. MELA: -10.00 )
MELA' s 10-Year EPS Growth (%) Range
Min: -28.9   Max: 34.6
Current: -10

-28.9
34.6
» MELA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

MELA Guru Trades in

MELA Guru Trades in

MELA Guru Trades in

Q2 2012

MELA Guru Trades in Q2 2012

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MELA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-06-30 Sold Out 0.01%$25.1 - $47.4 $ 1.74-95%0
George Soros 2012-03-31 Reduce -80%0.13%$32.1 - $48.2 $ 1.74-96%20000
George Soros 2011-12-31 New Buy0.16%$35 - $66.2 $ 1.74-97%100000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.27
MELA's P/B is ranked higher than
91% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. MELA: 1.27 )
MELA' s 10-Year P/B Range
Min: 1.26   Max: 6.36
Current: 1.27

1.26
6.36
P/S 14.35
MELA's P/S is ranked higher than
53% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.85 vs. MELA: 14.35 )
MELA' s 10-Year P/S Range
Min: 14.42   Max: 1330
Current: 14.35

14.42
1330
EV-to-EBIT -0.25
MELA's EV-to-EBIT is ranked higher than
57% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.54 vs. MELA: -0.25 )
MELA' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -0.25

Current Ratio 1.63
MELA's Current Ratio is ranked higher than
58% of the 305 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.81 vs. MELA: 1.63 )
MELA' s 10-Year Current Ratio Range
Min: 1.31   Max: 25.52
Current: 1.63

1.31
25.52
Quick Ratio 0.88
MELA's Quick Ratio is ranked higher than
53% of the 305 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.84 vs. MELA: 0.88 )
MELA' s 10-Year Quick Ratio Range
Min: 0.79   Max: 25.52
Current: 0.88

0.79
25.52

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 10.23
MELA's Price/Net Current Asset Value is ranked higher than
86% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. MELA: 10.23 )
MELA' s 10-Year Price/Net Current Asset Value Range
Min: 2.95   Max: 37.65
Current: 10.23

2.95
37.65
Price/Tangible Book 1.28
MELA's Price/Tangible Book is ranked higher than
94% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.41 vs. MELA: 1.28 )
MELA' s 10-Year Price/Tangible Book Range
Min: 2.13   Max: 18.29
Current: 1.28

2.13
18.29
Price/Median PS Value 0.21
MELA's Price/Median PS Value is ranked higher than
99% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.13 vs. MELA: 0.21 )
MELA' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 15.9
Current: 0.21

0.39
15.9
Forward Rate of Return (Yacktman) -430.67
MELA's Forward Rate of Return (Yacktman) is ranked lower than
51% of the 266 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.14 vs. MELA: -430.67 )
MELA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -430.67

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:E2ON.Germany
MELA Sciences, Inc. commenced operations in December 1989 as a New York corporation, re-incorporated as a Delaware corporation in September 1997, and changed its name from Electro-Optical Sciences, Inc. to MELA Sciences, Inc. April 30, 2010. The Company is a medical device company engaged in designing and development of a non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma. The Company's flagship product, MelaFind is a non-invasive and objective computer vision system intended to aid in the early detection of melanoma. The Company offers MelaFind to dermatologists as a non-invasive, point-of-care service that provides additional information about specific moles during a skin exam, which have one or more clinical or historical characteristics of melanoma, before a final decision to biopsy has been rendered. MelaFind(R) acquires and displays multi-spectral (from blue to near infrared) digital images of pigmented skin lesions and uses automatic image analysis and statistical pattern recognition to help identify lesions to be considered for biopsy to rule out melanoma. The Company's operations are confined to one business segment: the design, development and commercialization of MelaFind. The company's product MelaFind is regulated as a medical device and is subject to extensive regulation by the FDA and other regulatory authorities in the U.S.
» More Articles for MELA

Headlines

Articles On GuruFocus.com
own Mar 20 2013 
The Barclays Triggers More Insider Buying Mar 13 2013 
ElectroOptical Sciences Inc Reports Operating Results (10-K) Mar 03 2011 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) Nov 05 2010 
ElectroOptical Sciences Inc (MELA) CFO Richard I Steinhart buys 1,000 Shares Aug 12 2010 
ElectroOptical Sciences Inc (MELA) CEO Joseph V Gulfo buys 5,000 Shares Aug 12 2010 
ElectroOptical Sciences Inc (MELA) CEO Joseph V Gulfo buys 5,000 Shares Aug 12 2010 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) Aug 06 2010 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) May 10 2010 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) Nov 09 2009 

More From Other Websites
MELA Sciences to Provide Corporate Overview at the Craig-Hallum Capital Group's 2014 Alpha Select... Sep 15 2014
MELA Sciences to Provide Corporate Overview at the Rodman & Renshaw 16th Annual Global Investment... Sep 08 2014
MELA Sciences Collaborates With Columbia University Imaging Experts Aug 26 2014
MELA SCIENCES, INC. /NY Financials Aug 23 2014
UPDATE: H.C. Wainwright & Co. Initiates Coverage On MELA Sciences On Commercialization Strategy... Aug 18 2014
Coverage initiated on MELA Sciences by H.C. Wainwright Aug 18 2014
MELA SCIENCES, INC. /NY Files SEC form 10-Q, Quarterly Report Aug 14 2014
MELA Sciences Inc Earnings Call scheduled for 4:30 pm ET today Aug 13 2014
MELA Sciences Reports Second Quarter 2014 Financial Results and Provides a Business Update Aug 13 2014
Q2 2014 MELA Sciences Earnings Release - After Market Close Aug 13 2014
MELA Sciences to Host Analyst Meeting and Webcast on Wednesday, August 13 in New York City Aug 07 2014
MELA SCIENCES, INC. /NY Files SEC form 8-K, Financial Statements and Exhibits Aug 06 2014
MELA Sciences Names Michael R. Stewart to Board of Directors Aug 05 2014
MELA Sciences to Report Second Quarter 2014 Financial Results on Wednesday, August 13 Aug 04 2014
MELA SCIENCES, INC. /NY Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 29 2014
MELA Sciences Regains Compliance With NASDAQ Listing Requirements Jul 29 2014
MELA Sciences Reports the Closing of Its Private Placement Jul 25 2014
MELA Sciences Announces New Study Results Demonstrating Improved Diagnostic Accuracy for Resident... Jul 24 2014
MELA SCIENCES, INC. /NY Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of... Jul 23 2014
MELA Sciences Announces $27.3 Million At The Market Private Placement of Preferred Stock, Debentures... Jul 22 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK